10:18 AM EDT, 04/09/2025 (MT Newswires) -- OS Therapies ( OSTX ) said Wednesday it closed the acquisition of listeria-based cancer immunotherapy assets of Advaxis Immunotherapies from Ayala Pharmaceuticals.

The biopharmaceutical company said it has acquired clinical, preclinical, and intellectual property assets, including immunotherapy programs for human papilloma virus-associated cancers, non-small cell lung cancer, and prostate cancer.

OS Therapies ( OSTX ) said it is targeting the approval of its OST-HER2 immunotherapy candidate for fully resected, lung metastatic osteosarcoma by the end of 2025.

It also said that new manufacturing-based intellectual property protects the listeria-based immunotherapy platform and cancer immunotherapy candidates through 2040.

Price: 1.25, Change: -0.06, Percent Change: -4.58